Stockscreener 앱 받기
0.20%
전일 마감가:
$294.76
열려 있는:
$294.75
하루 거래량:
1.11M
Relative Volume:
0.42
시가총액:
$158.52B
수익:
$34.13B
순이익/손실:
$5.93B
주가수익비율:
26.90
EPS:
10.96
순현금흐름:
$10.92B
1주 성능:
-0.57%
1개월 성능:
+2.08%
6개월 성능:
+7.47%
1년 성능:
-10.85%
1일 변동 폭
$293.60
$297.09
1주일 범위
$291.94
$301.00
52주 변동 폭
$253.30
$346.85
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
AMGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
294.80 | 159.71B | 34.13B | 5.93B | 10.92B | 10.96 |
|
LLY
Lilly Eli Co
|
764.75 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.51 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
185.92 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.60 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
65.00 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Amgen’s Promising Study on Advanced Gastric Cancer: What Investors Need to Know - TipRanks
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Arrow Financial Corp - MarketBeat
Humira Biosimilar Market Gains Momentum Post-Patent Expiry & - openPR.com
Peregrine Asset Advisers Inc. Reduces Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
J.W. Cole Advisors Inc. Has $3.60 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer - GlobeNewswire Inc.
Larson Financial Group LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
What drives Amgen Inc. stock priceUnprecedented market success - Autocar Professional
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Forum Financial Management LP - MarketBeat
Amgen Stock (AMGN) Opinions on Recent Price Declines and Technical Trends - Quiver Quantitative
Los Angeles Capital Management LLC Increases Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Wealth Alliance LLC Acquires 999 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Souders Financial Advisors Sells 4,633 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Heritage Investors Management Corp Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Teachers Retirement System of The State of Kentucky Acquires 1,839 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Twin Capital Management Inc. Has $6.24 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Raised by OneAscent Financial Services LLC - MarketBeat
Elyxium Wealth LLC Invests $618,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Copperwynd Financial LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Rep. Cliff Bentz Purchases Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Evergreen Wealth Management LLC Has $2.64 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
What analysts say about Amgen Inc. stockConsistent double returns - jammulinksnews.com
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Verdence Capital Advisors LLC - MarketBeat
Parcion Private Wealth LLC Sells 1,188 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. Stock Analysis and ForecastPhenomenal wealth increase - Autocar Professional
Concord Wealth Partners Has $3.09 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Is Amgen Inc. a good long term investmentRapid market gains - jammulinksnews.com
SNS Financial Group LLC Reduces Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Balentine LLC Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Morningstar Investment Services LLC Sells 6,357 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by St. Louis Trust Co - MarketBeat
Private Advisor Group LLC Cuts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Position Cut by Jennison Associates LLC - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Edgestream Partners L.P. - MarketBeat
Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025 - Yahoo Finance
Amgen (AMGN) Declines More Than Market: Some Information for Investors - Yahoo Finance
Leo Wealth LLC Sells 1,746 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
HSBC Trims Amgen (AMGN) Price Target, Maintains Buy Rating - MSN
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More - Seeking Alpha
Amgen’s Phase 3 Study on Etelcalcetide: A Potential Game-Changer for Pediatric Kidney Disease - TipRanks
Amgen’s New Study on SCLC Treatment: A Potential Game Changer? - TipRanks
Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment - TipRanks
Amgen’s Romiplostim Study: A Potential Game-Changer for Chemotherapy Patients - TipRanks
Will Amgen Inc. stock benefit from interest rate changes2x 3x 5x Pick Alert - beatles.ru
Amgen’s Promising Phase 3 Study: Maridebart Cafraglutide for Obesity in Type 2 Diabetes - TipRanks
Amgen’s Avacopan Study: A Potential Game-Changer in Vasculitis Treatment - TipRanks
Amgen’s Promising Phase 3 Study on Metastatic Colorectal Cancer: A Potential Game-Changer - TipRanks
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome - TipRanks
Amgen’s Phase 2 Study on HZN-1116: A Potential Breakthrough for Sjögren’s Syndrome - TipRanks
Amgen and Novartis’s Erenumab Study: A Potential Game-Changer in Pediatric Migraine Treatment - TipRanks
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.08%
0.40%
자본화:
|
볼륨(24시간):